Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$129.46
$120.01
$73.04
$129.65
$8.36B0.891.54 million shsN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$14.78
-1.2%
$13.82
$8.02
$15.78
$7.43B1.675.03 million shs3.05 million shs
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$29.02
+0.6%
$27.90
$17.82
$30.69
$2.10B0.05558,527 shs841,396 shs
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$11.44
-1.8%
$11.16
$8.73
$13.06
$7.92B1.155.74 million shs4.93 million shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
+0.02%+0.14%+1.06%+53.01%+13.22%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-1.18%-0.78%+10.66%+75.04%+13.26%
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
+0.62%+3.31%+3.90%+43.59%+35.54%
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-1.80%+0.70%0.00%+12.71%+1.69%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.0742 of 5 stars
2.12.00.00.02.10.80.6
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.0415 of 5 stars
1.41.00.00.33.31.71.3
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.3517 of 5 stars
3.54.00.00.02.03.30.6
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
2.7307 of 5 stars
3.63.00.00.02.32.50.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
2.24
Hold$128.25-0.93% Downside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.88
Moderate Buy$16.008.25% Upside
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
3.00
Buy$39.3335.54% Upside
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
3.25
Buy$16.5044.23% Upside

Current Analyst Ratings Breakdown

Latest KNSA, BPMC, ROIV, and ELAN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/17/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$18.00
7/10/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$19.00
7/9/2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$30.00 ➝ $42.00
7/2/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$16.00 ➝ $17.00
6/26/2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform
6/18/2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$18.00
6/17/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold$143.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$102.00 ➝ $129.00
6/5/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$88.00 ➝ $129.00
6/4/2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong Sell ➝ Hold$83.00 ➝ $129.00
(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
$562.12M14.87N/AN/A$4.70 per share27.54
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.44B1.65$2.23 per share6.64$12.33 per share1.20
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$423.24M5.00N/AN/A$6.60 per share4.40
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
$29.05M267.71N/AN/A$7.45 per share1.54
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$67.09M-$2.47N/A199.17N/A-27.70%-64.60%-17.22%7/30/2025 (Estimated)
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$338M$0.7419.9716.612.928.43%7.54%3.57%8/7/2025 (Estimated)
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
-$43.19M-$0.25N/A116.08N/A-3.52%-3.83%-2.98%7/22/2025 (Estimated)
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$171.98M-$0.25N/AN/AN/A-225.71%-14.76%-13.69%8/6/2025 (Estimated)

Latest KNSA, BPMC, ROIV, and ELAN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q1 2026
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.23N/AN/AN/AN/AN/A
8/7/2025Q2 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.54N/AN/AN/A$171.34 millionN/A
8/7/2025Q2 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.1989N/AN/AN/A$1.19 billionN/A
7/22/2025Q2 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.08N/AN/AN/AN/AN/A
5/29/2025Q4 2025
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
-$0.16-$0.31-$0.15-$0.29$62.17 million$7.57 million
5/7/2025Q1 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.31$0.37+$0.06$0.14$1.17 billion$1.19 billion
5/1/2025Q1 2025
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
-$0.42-$0.74-$0.32$0.01$158.31 million$149.41 million
4/29/2025Q1 2025
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
$0.02$0.11+$0.09$0.11$128.35 million$137.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/AN/AN/AN/AN/A
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
1.01
2.80
2.75
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.68
2.71
1.46
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
N/A
3.66
3.43
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
N/A
33.47
33.47
CompanyEmployeesShares OutstandingFree FloatOptionable
Blueprint Medicines Corporation stock logo
BPMC
Blueprint Medicines
64064.58 million61.86 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,000496.65 million492.23 millionOptionable
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
22072.97 million33.95 millionOptionable
Roivant Sciences Ltd. stock logo
ROIV
Roivant Sciences
860679.81 million626.10 millionOptionable

Recent News About These Companies

Roivant Sciences Ltd. (ROIV) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Blueprint Medicines stock logo

Blueprint Medicines NASDAQ:BPMC

$129.46 0.00 (0.00%)
As of 07/18/2025

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$14.78 -0.18 (-1.20%)
Closing price 07/18/2025 03:59 PM Eastern
Extended Trading
$14.78 0.00 (-0.03%)
As of 07/18/2025 04:32 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Kiniksa Pharmaceuticals International stock logo

Kiniksa Pharmaceuticals International NASDAQ:KNSA

$29.02 +0.18 (+0.62%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$29.05 +0.03 (+0.10%)
As of 07/18/2025 05:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Roivant Sciences stock logo

Roivant Sciences NASDAQ:ROIV

$11.44 -0.21 (-1.80%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$11.44 0.00 (-0.03%)
As of 07/18/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.